For example, a recent phase-II clinical trial proved that the combination of ipilimumab (a CTLA-4 inhibitor) and nivolumab (a PD-1 inhibitor) significantly improved treatment efficacy in advanced melanoma patients compared with monotherapy with ipilimumab [43]. Here, CTLA4 is linked to melanoma.